Highline Capital Management, L.P. Voyager Therapeutics, Inc. Transaction History

Highline Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$16.31 - $28.29 $4.84 Million - $8.4 Million	-296,773 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$19.18 - $27.88 $5.6 Million - $8.14 Million	-292,024 Reduced 49.6%	296,773 $8.08 Million
Q1 2019 May 15, 2019	SELL	$8.0 - $19.66 $5.57 Million - $13.7 Million	-695,900 Reduced 54.17%	588,797 $11.3 Million
Q4 2018 Feb 14, 2019	BUY	$8.59 - $18.05 $2.43 Million - $5.11 Million	282,827 Added 28.23%	1,284,697 $12.1 Million
Q3 2018 Nov 14, 2018	BUY	$17.11 - $21.74 $2.76 Million - $3.5 Million	161,200 Added 19.18%	1,001,870 $19 Million
Q2 2018 Aug 14, 2018	BUY	$16.76 - $23.92 $14.1 Million - $20.1 Million	840,670 New	840,670 $16.4 Million

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $210M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.